Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













LY-320,135






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

LY-320,135
Identifiers

  • 4-[6-methoxy-2-(4-methoxyphenyl)1-benzofuran-3-carbonyl]benzonitrile

CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.190.302 Edit this at Wikidata
Chemical and physical data
FormulaC24H17NO4
Molar mass383.403 g·mol−1
3D model (JSmol)

  • c3cc(OC)ccc3-c2oc1cc(OC)ccc1c2C(=O)c4ccc(C#N)cc4

  • InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3

  • Key:RYNSGDFWBJWWSZ-UHFFFAOYSA-N

  (verify)

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s.

LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2,[1] but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.[2]

References[edit]

  1. ^ Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, et al. (January 1998). "LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation". The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 291–7. PMID 9435190.
  • ^ Pertwee RG (February 2005). "Inverse agonism and neutral antagonism at cannabinoid CB1 receptors". Life Sciences. 76 (12): 1307–24. doi:10.1016/j.lfs.2004.10.025. PMID 15670612.
    • Stub icon

    This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=LY-320,135&oldid=1215135371"
    Categories: 
    ●Cannabinoids
     ●CB1 receptor antagonists
     ●Benzofuran ethers at the benzene ring
     ●Resorcinol ethers
     ●Aromatic ketones
     ●Benzonitriles
     ●Drugs developed by Eli Lilly and Company
     ●Cannabinoid stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●ECHA InfoCard ID from Wikidata
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 23 March 2024, at 09:40 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki